ERCC1 mRNA expression is associated with the clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy

Genetics and Molecular Research

Volumn 13, Issue 4, 2014, Pages 10215-10222

  Zhang, H ^a   Li, J ^a   Zhang, Y ^a   Sun, M ^a   Zhao, P ^a   Zhang, G ^a   Jin, C ^a   Sun, L ^a   He, M ^a   Wang, B ^a   Zhang, X ^a  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Excision repair cross complementing group 1; mRNA; Non small cell lung cancer; Response to chemotherapy; Ribonucleotide reductase subunit M1; Survival

Indexed keywords

BETA ACTIN; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; COMPLEMENTARY DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; NAVELBINE; PACLITAXEL; RIBONUCLEOTIDE REDUCTASE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; MESSENGER RNA; RRM1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; ERCC1 GENE; FEMALE; FLUORESCENCE ANALYSIS; FOLLOW UP; GENE; GENE EXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROSPECTIVE STUDY; RRM1 GENE; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, MESSENGER; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84919354328     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.December.4.16     Document Type: Article

References (24)

1. Bartolucci R, Wei J, Sanchez JJ, Perez-Roca L, et al. (2009). XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin. Lung Cancer 10: 47-52.
2. Bepler G, Williams C, Schell MJ, Chen W, et al. (2013). Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 31: 2404-2412.
3. Bidoli P, Zilembo N, Cortinovis D, Mariani L, et al. (2007). Randomized phase II three-arm trial with three platinum-based doublets in metastatic non small-cell lung cancer. An Italian Trials in Medical Oncology Study. Ann. Oncol. 18: 461-467.
4. Cai Y, Geacintov NE and Broyde S (2012). Nucleotide excision repair efficiencies of bulky carcinogen-DNA adducts are governed by a balance between stabilizing and destabilizing interactions. Biochemistry 51: 1486-1499.
5. Chen S, Zhang J and Wang R (2010). The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70: 63-70.
6. Huang MY, Tsai HL, Lin CH, Huang CW, et al. (2013). Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy. J. Surg. Oncol. 108: 457-464.
7. International Agency for Research on Cancer (2008). Colorectal Cancer Incidence and Mortality Worldwide in 2008. [http://globocan. iarc. fr]. Accessed in 2013-10-1.
8. Johnson DH (2001). Gemcitabine for the treatment of non-small-cell lung cancer. Oncology (Williston Park) 15 (3 Suppl. 6): 33-39.
9. Jorgensen CL, Ejlertsen B, Bjerre KD, Balslev E, et al. (2013). Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine. BMC Cancer 13: 541.
10. Kotoula V, Krikelis D, Karavasilis V, Koletsa T, et al. (2012). Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS). BMC Cancer 12: 342.
11. Leng XF, Chen MW, Xian L, Dai L, et al. (2012). Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J. Exp. Clin. Cancer Res. 31: 25.
12. Li S, Wu J, Chen Y, Tang W, et al. (2014). ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis. Anticancer Drugs 25: 106-114.
13. Li Y, Liu Z, Liu H, Wang LE, et al. (2013). ERCC1 and ERCC2 variants predict survival in gastric cancer patients. PLoS One 8: e71994.
14. Mlak R, Krawczyk P, Ramlau R, Kalinka-Warzocha E, et al. (2013). Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum-and gemcitabine-based chemotherapy in non-small cell lung cancer patients. Oncol. Rep. 30: 2385-2398.
15. Ozdemir O, Ozdemir P, Veral A, Uluer H, et al. (2013). ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy. Asian Pac. J. Cancer Prev. 14: 4679-4683.
16. Pesta M, Kulda V, Fiala O, Safranek J, et al. (2012). Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. Anticancer Res. 32: 5003-5010.
17. Su C, Zhou S, Zhang L, Ren S, et al. (2011). ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med. Oncol. 28: 1411-1417.
18. Tantraworasin A, Saeteng S, Lertprasertsuke N, Arayawudhikul N, et al. (2013). The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival. Cancer Manag. Res. 5: 327-336.
19. Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, et al. (2013). Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. Lung Cancer 82: 324-329.
20. Vilmar A and Sorensen JB (2009). Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 64: 131-139.
21. Wang Q, Liu X, Zhou J, Huang Y, et al. (2013). Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer. PLoS One 8: e70191.
22. World Health Organization (1981). Histological typing of lung tumors. In: International histological classification of tumors. Vol. 1, 2nd edn. World Health Organization, Geneva.
23. Yamashita F, Azuma K, Yoshida T, Yamada K, et al. (2013). Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapy. PLoS One 8: e71356.
24. Zhang X, Jin FS, Zhang LG, Chen RX, et al. (2013) Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. Asian Pac. J. Cancer Prev. 14: 4261-4265.